Skip to main content

Advertisement

SpringerLink
Log in

Novel Cytotoxic Agents in the Treatment of Metastatic Breast Cancer

  • Systemic Therapy (J O’Shaughnessy, Section Editor)
  • Published:
Current Breast Cancer Reports Aims and scope Submit manuscript

Abstract

Breast cancer is the most common cancer affecting women worldwide, comprising approximately 20% of all cancers. Although many advances in the treatment of this disease have been made and mortality of early breast cancer improved over the past three decades, metastatic breast cancer (MBC) remains an incurable disease. Cytotoxic chemotherapy continues to play a major role in the treatment of MBC and has been recently combined with biologic agents such as monoclonal antibodies or kinase inhibitors. Over the past decade, several novel cytotoxic chemotherapies have been evaluated in clinical trials. Encouraging results have been observed with novel anti-microtubule agents, with recent US Food and Drug Administration approval of eribulin in 2010. Other novel cytotoxic agents currently under clinical development include novel anti-microtubule drugs, platinum compounds, and anti-angiogenic agents combined with chemotherapy. Here, we review all the major novel cytotoxic agents that have undergone clinical study over the past 5 years for the treatment of MBC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance, •• Of major importance

  1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36.

    Article  PubMed  Google Scholar 

  2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225–49.

    Article  PubMed  Google Scholar 

  3. American Cancer Society. Cancer facts & figures 2011. Atlanta: American Cancer Society; 2011.

    Google Scholar 

  4. Carlson RW, Allred DC, Anderson BO, et al. Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009;7:122–92.

    PubMed  CAS  Google Scholar 

  5. Anderson WF, Chu KC, Chatterjee N, et al. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database. J Clin Oncol. 2001;19:18–27.

    PubMed  CAS  Google Scholar 

  6. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.

    Article  PubMed  CAS  Google Scholar 

  7. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009;9:S73–81.

    Article  PubMed  CAS  Google Scholar 

  8. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.

    Article  PubMed  CAS  Google Scholar 

  9. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360:790–800.

    Article  PubMed  CAS  Google Scholar 

  10. Hernandez-Aya LF, Chavez-Macgregor M, Lei X, et al. Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer. J Clin Oncol. 2011;29:2628–34.

    Article  PubMed  Google Scholar 

  11. Ismail-Khan R, Bui MM. A review of triple-negative breast cancer. Cancer Control. 2010;17:173–6.

    PubMed  Google Scholar 

  12. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science. 1994;266:1821–8.

    Article  PubMed  CAS  Google Scholar 

  13. Montero AJ, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 2005;6:229–39.

    Article  PubMed  CAS  Google Scholar 

  14. Montero AJ, Jassem J. Cellular redox pathways as a therapeutic target in the treatment of cancer. Drugs. 2011;71:1385–96.

    Article  PubMed  CAS  Google Scholar 

  15. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature. 1979;277:665–7.

    Article  PubMed  CAS  Google Scholar 

  16. Cortes J, Roche H: Docetaxel combined with targeted therapies in metastatic breast cancer. Cancer 2011, Epub ahead of print.

  17. Ganansia-Leymarie V, Bischoff P, Bergerat JP, Holl V. Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anticancer Agents. 2003;3:291–306.

    Article  PubMed  CAS  Google Scholar 

  18. Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev. 2008;60:876–85.

    Article  PubMed  CAS  Google Scholar 

  19. ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42:665–85.

    Article  PubMed  Google Scholar 

  20. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm. 2002;235:179–92.

    Article  PubMed  CAS  Google Scholar 

  21. van Zuylen L, Verweij J, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs. 2001;19:125–41.

    Article  PubMed  Google Scholar 

  22. Montero AJ, Adams B, Diaz-Montero CM, Gluck S. Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review. Expert Rev Clin Pharmacol. 2011;4:329–34.

    Article  PubMed  CAS  Google Scholar 

  23. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794–803.

    Article  PubMed  CAS  Google Scholar 

  24. Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001;61:1013–21.

    PubMed  CAS  Google Scholar 

  25. •• Cortes J, O’Shaughnessy J, Loesch D, et al.: Eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011, 377:914–23. This phase III trial compared eribulin to treatment of physician’s choice (TPC) in 762 patients with previously treated locally recurrent or MBC. The median OS in the eribulin group was 13.1 months, compared to 10.7 months in the TPC arm. Median PFS and ORR favored eribulin as well.The overall incidence of peripheral neuropathy with eribulin (35%) was lower than what was observed in the TPC group (45%). There was an 8% rate of grade 3–4 peripheral neuropathy reported with eribulin.

  26. Hennenfent KL, Govindan R. Novel formulations of taxanes: a review Old wine in a new bottle? Ann Oncol. 2006;17:735–49.

    Article  PubMed  CAS  Google Scholar 

  27. Twelves C, Cortes J, Vahdat LT, et al. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer. 2010;10:160–3.

    Article  PubMed  CAS  Google Scholar 

  28. Bissery MC. Preclinical evaluation of new taxoids. Curr Pharm Des. 2001;7:1251–7.

    Article  PubMed  CAS  Google Scholar 

  29. •• Dieras V, Limentani S, Romieu G, et al.: Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann Oncol 2008, 19:1255–60. In this phase II trial, 130 women with MBC who had received a taxane-based chemotherapy as first-line therapy received larotaxel. Patients were stratified based on prior response to taxanes. Patients with taxane-nonresistant disease had higher ORR (42% vs 19%), longer median TTP (5.4 months vs 1.6 months), and longer median OS times (22.6 months vs 9.8 months) when compared to those with taxane-resistant disease. Adverse toxicities were favorable when compared to what is typically observed with taxane-based chemotherapy.

  30. Shionoya M, Jimbo T, Kitagawa M, et al. DJ-927, a novel oral taxane, overcomes P-glycoprotein-mediated multidrug resistance in vitro and in vivo. Cancer Sci. 2003;94:459–66.

    Article  PubMed  CAS  Google Scholar 

  31. Schwartzberg LS, Beeram M, Patnaik A, et al.: Tesetaxel, an advanced-generation oral taxane, as first-line treatment in women with metastatic breast cancer [abstract TPS123]. Presented at the 2011 ASCO Annual Meeting. Chicago, Illinois; June 3–7, 2011.

  32. Cisternino S, Bourasset F, Archimbaud Y, et al. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br JPharmacol. 2003;138:1367–75.

    Article  CAS  Google Scholar 

  33. Villanueva C, Awada A, Campone M, et al. A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. Eur J Cancer. 2011;47:1037–45.

    Article  PubMed  CAS  Google Scholar 

  34. Gale S, Croasdell G. 28th Annual JPMorgan healthcare conference–exelixis and nektar therapeutics. IDrugs. 2010;13:139–41.

    PubMed  Google Scholar 

  35. Awada A, Chan S, Jerusalem GHM, et al.: Antitumor activity in a randomized phase II study comparing two schedules of NKTR-102 in patients (Pts) with pretreated metastatic breast cancer (MBC) [abstract 1034]. Presented at the 2011 ASCO Annual Meeting. Chicago, Illinois; June 3–7, 2011.

  36. Choy H. Satraplatin: an orally available platinum analog for the treatment of cancer. Expert RevAnticancer Ther. 2006;6:973–82.

    Article  CAS  Google Scholar 

  37. Smith JW, McIntyre KJ, Acevedo P, et al.: A phase II trial of oral satraplatin in patients with metastatic breast cancer [abstract 153]. Presented at the 2007 Breast Cancer Symposium. San Francisco, California; September 7-8, 2007.

  38. McLeod HL, Cassidy J, Powrie RH, et al. Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034. Clin Cancer Res. 2000;6:2677–84.

    PubMed  CAS  Google Scholar 

  39. Martin M, Blasinska-Morawiec M, Salas JF, et al. A multicenter, single-arm phase II study of pemetrexed plus doxorubicin administered every 21 days in patients with advanced breast cancer. ClinBreast Cancer. 2009;9:155–60.

    CAS  Google Scholar 

  40. Dent SF, Gertler S, Verma S, et al. A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 2010;65:557–61.

    Article  PubMed  CAS  Google Scholar 

  41. Pippen J, Elias AD, Neubauer M, et al. A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy. Clin Breast Cancer. 2010;10:148–53.

    Article  PubMed  CAS  Google Scholar 

  42. Schneeweiss A, Marme F, Ruiz A, et al. A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer. Ann Oncol. 2011;22:609–17.

    Article  PubMed  CAS  Google Scholar 

  43. Robert NJ, Conkling PR, O’Rourke MA, et al. Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer. Breast Cancer Res Treat. 2011;126:101–8.

    Article  PubMed  CAS  Google Scholar 

  44. D'Incalci M, Colombo T, Ubezio P, et al. The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer. 2003;39:1920–6.

    Article  PubMed  Google Scholar 

  45. Zelek L, Yovine A, Brain E, et al. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer. 2006;94:1610–4.

    Article  PubMed  CAS  Google Scholar 

  46. Tedesco KL, Blum JL, Goncalves A, et al.: Final results of a phase II trial of trabectedin (T) in triple-negative, HER2-positive, and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts) [abstract 1125]. Presented at the 2011 ASCO Annual Meeting. Chicago, Illinois; June 3–7, 2011.

  47. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–76.

    Article  PubMed  CAS  Google Scholar 

  48. Montero AJ, Escobar M, Lopes G, et al.: Bevacizumab in the treatment of metastatic breast cancer: friend or foe? Curr Oncol Rep 2011, Epub ahead of print.

  49. Mayer EL, Dhakil S, Patel T, et al. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol. 2010;21:2370–6.

    Article  PubMed  CAS  Google Scholar 

  50. Bergh J, Greil R, Voytko N, et al.: Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC) [abstract LBA1010]. Presented at the 2010 ASCO Annual Meeting; June 4–8, 2010.

  51. Barrios CH, Liu MC, Lee SC, et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res Treat. 2010;121:121–31.

    Article  PubMed  CAS  Google Scholar 

  52. • Martin M, Roche H, Pinter T, et al.: Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2011, 12:369–76. This triple-arm phase II study gave 282 women with MBC paclitaxel combined with either motesanib, bevacizumab, or placebo. There was not a significant difference in ORR between the three groups. Serious adverse events were more common in the motesanib group, the most frequent being gastrointestinal in nature. The results of this study are in line with those seen in E2100.

  53. Rastogi P, Buyse ME, Tan AR, et al.: A phase II clinical trial of four cycles of doxorubicin and cyclophosphamide followed by weekly paclitaxel given concurrently with pazopanib as neoadjuvant therapy followed by postoperative pazopanib for women with locally advanced breast cancer (LABC): A phase II trial of the NSABP Foundation Research Group (FB-6/VEG110264) [abstract TPS107]. Presented at the 2010 ASCO Annual Meeting; June 4–8, 2010.

  54. Wang L, Chen J, Yao Q, et al.: Neoadjuvant rh-endostatin, docetaxel, and epirubicin for breast cancer: Efficacy and safety in a prospective, randomized, phase II study [abstract 1132]. Presented at the 2011 ASCO Annual Meeting; June 3–7, 2011.

  55. Dieras V, Jassem J, Dirix LY, et al.: A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC) [abstract 544]. Presented at the 2011 ASCO Annual Meeting; June 3-7, 2011.

  56. Modi S, Saura C, Henderson CA, et al.: Efficacy and safety of retaspimycin hydrochloride (IPI-504) in combination with trastuzumab in patients (pts) with pretreated, locally advanced or metastatic HER2-positive breast cancer [abstract 590]. Presented at the 2011 ASCO Annual Meeting; June 3-7, 2011.

  57. Mayer EL, Scheulen ME, Beckman J, et al.: Combination of tivozanib (AV-951) with weekly paclitaxel for metastatic breast cancer: Results of a phase I study [abstract 1092]. Presented at the 2011 ASCO Annual Meeting; June 3-7, 2011.

  58. Tiersten A, Schneider BP, Dickler M, et al.: Administration of the Novel Antiangiogenic PTC299 in Combination with Aromatase Inhibitors Is Feasible and Shows Antitumor Activity in Metastatic Breast Cancer [abstract P2-16-08]. Presented at the San Antonio Breast Cancer Symposium. San Antonio, Texas; December 8–12, 2010.

  59. Mackey J, Gelmon K, Martin M, et al. TRIO-012: a multicenter, multinational, randomized, double-blind phase III study of IMC-1121B plus docetaxel versus placebo plus docetaxel in previously untreated patients with HER2-negative, unresectable, locally recurrent or metastatic breast cancer. Clin Breast Cancer. 2009;9:258–61.

    Article  PubMed  CAS  Google Scholar 

  60. Lobo C, Lopes G, Baez O, et al. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2010;123:427–35.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

S. Warsch: none; A.J. Montero: none; S. Glück has received honoraria from and is a board member (unpaid) of Bristol-Myers Squibb, Eisai, Genentech, and Celgene.

Author information

Authors and Affiliations

  1. Department of Medicine, University of Miami, 1475 NW 12th Avenue, Suite 3310, Miami, FL, 33136, USA

    Sean Warsch

  2. Division of Hematology and Oncology, Department of Medicine, University of Miami, 1475 NW 12th Avenue, Suite 3310, Miami, FL, 33136, USA

    Alberto J. Montero & Stefan Glück

Authors
  1. Sean Warsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alberto J. Montero
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefan Glück
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Glück.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Warsch, S., Montero, A.J. & Glück, S. Novel Cytotoxic Agents in the Treatment of Metastatic Breast Cancer. Curr Breast Cancer Rep 4, 75–82 (2012). https://doi.org/10.1007/s12609-011-0066-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12609-011-0066-0

Keywords

Search

Navigation